Table 1.

Characteristics of the observational studies included in the meta-analysis.

Study	Design	Participants (n)	Females	Age Mean, Years (SD)	Age at Onset Mean, Years (SD)	Diagnoses	Pramipexole Mean Maximum Dose	Trial Duration (Weeks)	Outcome Measure	Response Criteria	Remission Criteria
Cassano et al., 2004 [80]	Prospective	23	69.5%	52.8 (12.5)	35.1 (16)	11 MDD; 12 BD	0.99	48	LIFE	Not reported	Depression score ≤ 2
Hori et al., 2012 [49]	Open-label trial	17	58.8%	36.2 (9.2)	28.1 (7.6)	12 MDD; 5 BD	1.6	12	HDRS	>50% total score reduction	Total score ≤ 7
Inoue et al., 2010 [81]	Open-label trial	10	40%	43.7 (11.4)	39.6 (11.5)	10 MDD	1.3	8	MADRS	>50% total score reduction	Total score < 10
Lattanzi et al., 2002 [82]	Prospective	31	67.7%	53.7 (13.5)	32 (15.3)	14 MDD; 17 BD	0.95	16	MADRS	>50% total score reduction	Not reported
Perugi et al., 2001 [83]	Retrospective	10	60%	55 (15.9)	34.2 (14.8)	10 BD	1.23	17.6	CGI	Improvement score = 2	Improvement score = 1
Sporn et al., 2000 [84]	Retrospective	32	53.1%	41.5 (14)	22.3 (10.8)	20 MDD; 12 BD	0.69	24.4	CGI	Improvement score ≤ 2	Not reported
Fawcett et al., 2016 [85]	Case series	42	50%	53.97 (13)	NR	24 MDD; 18 BD	2.18	69	Clinical	Clinical assessment	Clinical assessment
Tundo et al., 2022 [86]	Prospective	116	56%	62.2 (13.3)	44.4 (17.9)	79 MDD; 37 BD	1.03	24	HDRS	>50% total score reduction	Total score < 7

Abbreviations: BD = bipolar disorder; MDD = major depressive disorder.